Phase II study of Polatuzumab vedotin in combination with chemotherapy in subjects with Richter's Transformation
Study of Polatuzumab Vedotin in Combination with Chemotherapy in Subjectswith Richter's Transformation
Sponsor: Genentech
Enrolling: Male and Female Patients
IRB Number: AAAT9408
U.S. Govt. ID: NCT04679012
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: This research is being done because Richter's transformation, which is a life-threatening complication of chronic lymphocytic lymphoma (CLL), and is associated with poor overall survival rate. The study drug administration is a combination of the investigational drug, Polatuzumab vedotin, in combination with Rituximab, Etoposide, Prednisone, Cyclophosphamide, and Hydroxydaunorubicin, also referred to as PolaR-EPCH. An investigational drug means it has not been approved by the FDA or any other international regulatory agencies. The purpose of this study is to find out what effects the study drug, Polatuzumab vedotin, in combination with a standard chemoimmunotherapy regimen has on subjects with Richter's Transformation. Additionally, we would like to see how safe the study drug administration is for subjects with Richter's Transformation.
Andrew Lipsky, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Do you have a life expectancy of at least 24 weeks? Yes No
Have you previously had therapy for Richters Transformation? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator